View Financial HealthStablecoin Development 배당 및 자사주 매입배당 기준 점검 2/6Stablecoin Development 은(는) 현재 수익률이 154.98% 인 배당금 지급 회사입니다.핵심 정보155.0%배당 수익률-50.4%자사주 매입 수익률총 주주 수익률-50.4%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트공시 • Aug 28NovaBay Pharmaceuticals, Inc. announces special dividend, payable on September 29, 2025NovaBay Pharmaceuticals, Inc. announced special dividend of USD 0.8000 per share payable on September 29, 2025, ex-date on September 30, 2025 and record date on September 15, 2025.모든 업데이트 보기Recent updates공시 • Jan 20NovaBay Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.NovaBay Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering공시 • Sep 12NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025.공시 • Aug 28NovaBay Pharmaceuticals, Inc. announces special dividend, payable on September 29, 2025NovaBay Pharmaceuticals, Inc. announced special dividend of USD 0.8000 per share payable on September 29, 2025, ex-date on September 30, 2025 and record date on September 15, 2025.공시 • Aug 22+ 2 more updatesNovabay Pharmaceuticals, Inc. Chief Executive Officer Changes, Effective August 19, 2025On August 19, 2025 and effective at the First Closing, Justin Hall voluntarily resigned as the Chief Executive Officer of the NovaBay Pharmaceuticals, Inc., though he will remain a named executive officer of the Company and serve as the Vice President of Business Development, General Counsel and Corporate Secretary of the Company (as further described in subpart (e) below) as well as a director serving on the Board. Appointment of David Lazar as Chief Executive Officer, Effective Immediately. Mr. Lazar, age 35, previously served as director on the board of directors of FiEE, Inc. (formerly Minim, Inc.) where he also previously served as the Chief Executive Officer and Chief Financial Officer from December 2023 to February 2025. Mr. Lazar served as interim Chief Executive Officer and principal financial officer of Cyclacel Pharmaceuticals, Inc., from January 2, 2025 through February 26, 2025. Mr. Lazar served as the Chief Executive Officer of Titan Pharmaceuticals Inc. listed on Nasdaq from August 2022 to April 2024, where he also served as a director and board chairman from August 2022 until October 2023. Mr. Lazar also served as the chief executive officer and chairman of the board of directors of OpGen, Inc. from March 2024 to August 2024. Mr. Lazar also served as the president and a member of the board of directors of LQR House Inc. from October 2024 to April 2025.공시 • Aug 20NovaBay Pharmaceuticals, Inc. announced that it expects to receive $6 million in fundingNovaBay Pharmaceuticals, Inc entered into a subscription agreement to issue 481,250 shares of Series D non-voting convertible preferred stock at an issue price of $8 for the proceeds of $3,850,000 and 268,750 shares of Series E non-voting convertible preferred stock at an issue price of $8 for the proceeds of $2,150,000 on August 19, 2025. The transaction involves participation of David E. Lazar as an investor. On the same day, company closed the first tranche of Series D non-voting convertible preferred stock for the proceeds of $3,850,000. The Purchase Agreement also contemplates that Mr. Lazar will separately purchase and acquire 268,750 shares of Series E Preferred Stock as soon as practicable after the Company receives the Conversion Approval subject to shareholder approval공시 • Apr 02NovaBay Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/01/2025, NovaBay Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Oct 30RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million.RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million on October 29, 2024. Refresh’s unsolicitedoffer provides for terms that are substantially similar to the contemplated transaction with PRN, except that the Company would receive a purchase price of up to $11.5 million (compared with $9.5 million in the transaction with PRN), subject to a downside net working capital adjustment. Refresh’s unsolicitedoffer also includes Refresh providing a secured term loan to the Company in the principal amount of $2.0 million, which is expected to be repaid upon closing and deducted from the purchase price.공시 • Aug 02NovaBay Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024공시 • Jul 27NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,200,380 Price\Range: $1.1 Security Name: Series F-1 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Series F-3 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Series F-2 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380공시 • Jul 13Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024NovaBay Pharmaceuticals, Inc. provided revenue guidance for the year 2024. The company expects 2024 net revenue from the Company’s eyecare products to be approximately $10 million.공시 • Apr 20NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024, at 11:00 Pacific Daylight. Agenda: To elect three Class II directors nominated by our Board of Directors to hold office for a term of three years or until their respective successors are elected and qualified; to consider ratifying the appointment by our Audit Committee of WithumSmith+Brown, PC as our independent registered public accounting firm; to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of all of our Common Stock issued and outstanding; to grant authorization to our Board of Directors to determine, in its sole discretion, the specific ratio at any whole number within such share range and the timing of the Reverse Stock Split becoming effective or to abandon the Reverse Stock Split; to adjourn the Annual Meeting to establish a quorum or to permit further solicitation of proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve the proposals; and to consider other matters.공시 • Mar 26+ 1 more updateNew Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY).New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million on March 12, 2024. The Closing is subject to certain conditions that include the Company obtaining the consent of the holders of the Company’s Original Discount Senior Secured Convertible Debentures due November 1, 2024 (the “ Convertible Notes ”) to (1) amend the Security Agreement, dated April 27, 2023, to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Convertible Notes and for DERMAdoctor to be removed as a party to such agreement and (2) terminate the Subsidiary Guarantee, dated April 27, 2023, which DERMAdoctor entered into in connection with the issuance of the Convertible Notes. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. Yaacov Brenenson of Squire Patton Boggs (US) LLP acted as legal counsel for NovaBay. New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) on March 25, 2024.공시 • Mar 15New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million.New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million on March 12, 2024. The Closing is subject to certain conditions that include the Company obtaining the consent of the holders of the Company’s Original Discount Senior Secured Convertible Debentures due November 1, 2024 (the “ Convertible Notes ”) to (1) amend the Security Agreement, dated April 27, 2023, to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Convertible Notes and for DERMAdoctor to be removed as a party to such agreement and (2) terminate the Subsidiary Guarantee, dated April 27, 2023, which DERMAdoctor entered into in connection with the issuance of the Convertible Notes. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. Yaacov Brenenson of Squire Patton Boggs (US) LLP acted as legal counsel for NovaBay.공시 • Nov 03NovaBay Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023공시 • Aug 09NovaBay Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023공시 • May 19NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023, at 11:00 Pacific Daylight. Agenda: To consider directorate elections; to ratify the appointment by the Audit Committee of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider adjourn the Annual Meeting to establish a quorum or to permit further solicitation of proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve the proposals; and to consider other matters.공시 • May 05NovaBay Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q1, 2023 results After-Market on May 11, 2023공시 • Feb 02NovaBay Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 23, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 23, 2023지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 B9P1 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: B9P1 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Stablecoin Development 배당 수익률 vs 시장B9P1의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (B9P1)155.0%시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.7%업계 평균 (Pharmaceuticals)2.7%분석가 예측 (B9P1) (최대 3년)n/a주목할만한 배당금: B9P1 의 배당금( 154.98% )은 German 시장에서 배당금 지급자의 하위 25%( 1.5% )보다 높습니다.고배당: B9P1 의 배당금( 154.98% )은 German 시장( 4.65% )주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 B9P1 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: B9P1 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 11:56종가2026/02/20 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Stablecoin Development Corporation는 8명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Edward WooAscendiant Capital Markets LLCPooya HemamiDesjardins Securities Inc.Christian GlennieEdison Investment Research5명의 분석가 더 보기
공시 • Aug 28NovaBay Pharmaceuticals, Inc. announces special dividend, payable on September 29, 2025NovaBay Pharmaceuticals, Inc. announced special dividend of USD 0.8000 per share payable on September 29, 2025, ex-date on September 30, 2025 and record date on September 15, 2025.
공시 • Jan 20NovaBay Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.NovaBay Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Sep 12NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025.
공시 • Aug 28NovaBay Pharmaceuticals, Inc. announces special dividend, payable on September 29, 2025NovaBay Pharmaceuticals, Inc. announced special dividend of USD 0.8000 per share payable on September 29, 2025, ex-date on September 30, 2025 and record date on September 15, 2025.
공시 • Aug 22+ 2 more updatesNovabay Pharmaceuticals, Inc. Chief Executive Officer Changes, Effective August 19, 2025On August 19, 2025 and effective at the First Closing, Justin Hall voluntarily resigned as the Chief Executive Officer of the NovaBay Pharmaceuticals, Inc., though he will remain a named executive officer of the Company and serve as the Vice President of Business Development, General Counsel and Corporate Secretary of the Company (as further described in subpart (e) below) as well as a director serving on the Board. Appointment of David Lazar as Chief Executive Officer, Effective Immediately. Mr. Lazar, age 35, previously served as director on the board of directors of FiEE, Inc. (formerly Minim, Inc.) where he also previously served as the Chief Executive Officer and Chief Financial Officer from December 2023 to February 2025. Mr. Lazar served as interim Chief Executive Officer and principal financial officer of Cyclacel Pharmaceuticals, Inc., from January 2, 2025 through February 26, 2025. Mr. Lazar served as the Chief Executive Officer of Titan Pharmaceuticals Inc. listed on Nasdaq from August 2022 to April 2024, where he also served as a director and board chairman from August 2022 until October 2023. Mr. Lazar also served as the chief executive officer and chairman of the board of directors of OpGen, Inc. from March 2024 to August 2024. Mr. Lazar also served as the president and a member of the board of directors of LQR House Inc. from October 2024 to April 2025.
공시 • Aug 20NovaBay Pharmaceuticals, Inc. announced that it expects to receive $6 million in fundingNovaBay Pharmaceuticals, Inc entered into a subscription agreement to issue 481,250 shares of Series D non-voting convertible preferred stock at an issue price of $8 for the proceeds of $3,850,000 and 268,750 shares of Series E non-voting convertible preferred stock at an issue price of $8 for the proceeds of $2,150,000 on August 19, 2025. The transaction involves participation of David E. Lazar as an investor. On the same day, company closed the first tranche of Series D non-voting convertible preferred stock for the proceeds of $3,850,000. The Purchase Agreement also contemplates that Mr. Lazar will separately purchase and acquire 268,750 shares of Series E Preferred Stock as soon as practicable after the Company receives the Conversion Approval subject to shareholder approval
공시 • Apr 02NovaBay Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/01/2025, NovaBay Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Oct 30RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million.RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million on October 29, 2024. Refresh’s unsolicitedoffer provides for terms that are substantially similar to the contemplated transaction with PRN, except that the Company would receive a purchase price of up to $11.5 million (compared with $9.5 million in the transaction with PRN), subject to a downside net working capital adjustment. Refresh’s unsolicitedoffer also includes Refresh providing a secured term loan to the Company in the principal amount of $2.0 million, which is expected to be repaid upon closing and deducted from the purchase price.
공시 • Aug 02NovaBay Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024
공시 • Jul 27NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,200,380 Price\Range: $1.1 Security Name: Series F-1 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Series F-3 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Series F-2 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380
공시 • Jul 13Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024NovaBay Pharmaceuticals, Inc. provided revenue guidance for the year 2024. The company expects 2024 net revenue from the Company’s eyecare products to be approximately $10 million.
공시 • Apr 20NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024, at 11:00 Pacific Daylight. Agenda: To elect three Class II directors nominated by our Board of Directors to hold office for a term of three years or until their respective successors are elected and qualified; to consider ratifying the appointment by our Audit Committee of WithumSmith+Brown, PC as our independent registered public accounting firm; to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of all of our Common Stock issued and outstanding; to grant authorization to our Board of Directors to determine, in its sole discretion, the specific ratio at any whole number within such share range and the timing of the Reverse Stock Split becoming effective or to abandon the Reverse Stock Split; to adjourn the Annual Meeting to establish a quorum or to permit further solicitation of proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve the proposals; and to consider other matters.
공시 • Mar 26+ 1 more updateNew Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY).New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million on March 12, 2024. The Closing is subject to certain conditions that include the Company obtaining the consent of the holders of the Company’s Original Discount Senior Secured Convertible Debentures due November 1, 2024 (the “ Convertible Notes ”) to (1) amend the Security Agreement, dated April 27, 2023, to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Convertible Notes and for DERMAdoctor to be removed as a party to such agreement and (2) terminate the Subsidiary Guarantee, dated April 27, 2023, which DERMAdoctor entered into in connection with the issuance of the Convertible Notes. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. Yaacov Brenenson of Squire Patton Boggs (US) LLP acted as legal counsel for NovaBay. New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) on March 25, 2024.
공시 • Mar 15New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million.New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million on March 12, 2024. The Closing is subject to certain conditions that include the Company obtaining the consent of the holders of the Company’s Original Discount Senior Secured Convertible Debentures due November 1, 2024 (the “ Convertible Notes ”) to (1) amend the Security Agreement, dated April 27, 2023, to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Convertible Notes and for DERMAdoctor to be removed as a party to such agreement and (2) terminate the Subsidiary Guarantee, dated April 27, 2023, which DERMAdoctor entered into in connection with the issuance of the Convertible Notes. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. Yaacov Brenenson of Squire Patton Boggs (US) LLP acted as legal counsel for NovaBay.
공시 • Nov 03NovaBay Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023
공시 • Aug 09NovaBay Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023
공시 • May 19NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023, at 11:00 Pacific Daylight. Agenda: To consider directorate elections; to ratify the appointment by the Audit Committee of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider adjourn the Annual Meeting to establish a quorum or to permit further solicitation of proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve the proposals; and to consider other matters.
공시 • May 05NovaBay Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q1, 2023 results After-Market on May 11, 2023
공시 • Feb 02NovaBay Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 23, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 23, 2023